These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1254 related articles for article (PubMed ID: 20017617)
21. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation. Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815 [TBL] [Abstract][Full Text] [Related]
22. Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Ozkan E; Aras G; Kucuk NO Clin Nucl Med; 2013 May; 38(5):326-31. PubMed ID: 23486319 [TBL] [Abstract][Full Text] [Related]
23. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081 [TBL] [Abstract][Full Text] [Related]
24. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? Mazzaferri EL; Kloos RT J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270 [TBL] [Abstract][Full Text] [Related]
25. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels. Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014 [TBL] [Abstract][Full Text] [Related]
26. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522 [TBL] [Abstract][Full Text] [Related]
27. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience. Bertagna F; Albano D; Bosio G; Piccardo A; Dib B; Giubbini R Curr Radiopharm; 2016; 9(3):228-234. PubMed ID: 27210819 [TBL] [Abstract][Full Text] [Related]
28. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer. Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523 [TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202 [TBL] [Abstract][Full Text] [Related]
30. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Lind P; Kohlfürst S Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610 [TBL] [Abstract][Full Text] [Related]
32. Follow-up of differentiated thyroid cancer. Pacini F Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551 [TBL] [Abstract][Full Text] [Related]
33. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605 [TBL] [Abstract][Full Text] [Related]
34. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy. Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820 [TBL] [Abstract][Full Text] [Related]
35. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer. Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259 [TBL] [Abstract][Full Text] [Related]
36. Clinical and pathological factors related to 18F-FDG-PET positivity in the diagnosis of recurrence and/or metastasis in patients with differentiated thyroid cancer. Esteva D; Muros MA; Llamas-Elvira JM; Jiménez Alonso J; Villar JM; López de la Torre M; Muros T Ann Surg Oncol; 2009 Jul; 16(7):2006-13. PubMed ID: 19415387 [TBL] [Abstract][Full Text] [Related]
37. F-18 FDG-PET/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level. Bertagna F; Bosio G; Biasiotto G; Rodella C; Puta E; Gabanelli S; Lucchini S; Merli G; Savelli G; Giubbini R; Rosenbaum J; Alavi A Clin Nucl Med; 2009 Nov; 34(11):756-61. PubMed ID: 19851169 [TBL] [Abstract][Full Text] [Related]
38. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Ong SC; Ng DC; Sundram FX Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358 [TBL] [Abstract][Full Text] [Related]
39. [Use of 18F FDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative ¹³¹I scan]. Sanz Viedma S; Borrego Dorado I; Rodríguez Rodríguez JR; Navarro González E; Vázquez Albertino R; Fernández López R; Agudo Martínez A Rev Esp Med Nucl; 2011; 30(2):77-82. PubMed ID: 21334773 [TBL] [Abstract][Full Text] [Related]
40. [Application of recombinant human TSH in the diagnostic protocol of differentiated thyroid carcinoma]. Jiménez-Hoyuela García JM; García Almeida JM; Delgado García A; Aguilar Fernández I; Martínez del Valle Torres MD; Ortega Lozano S; Rebollo Aguirre A; Mancha Doblas I; Pinzón Martín JL; Picón César MJ; Zamorano Vázquez D Rev Esp Med Nucl; 2005; 24(3):152-60. PubMed ID: 15847782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]